Home › Research › Topics › costs
costs
265 studies tagged costs, dated 1989-11-10 to 2026-10-28. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- The Contribution of Routinely Collected Clinical Data to Dementia Identification in Primary Care: A Cross-Sectional Study 2026-10-28
- Racial Differences and Temporal Trends in Parkinson’s and Alzheimer’s Disease-Related 2026-10-24
- Prognostic heterogeneity within cognitive stages: a nationwide cohort study of everyday functional difficulties and mortality in 202,508 older adults 2026-10-23
Studies
265 studies carry this tag.
Date range
1989 to 2026
Top journals
- Alzheimer's & dementia : the journal of the Alzheimer's Association 38
- Journal of the American Geriatrics Society 21
- medRxiv 19
- Journal of Alzheimer's disease : JAD 15
- Research Square 15
104 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Sociodemographic and clinical variables routinely recorded in PC EHRs may contribute to dementia identification.
-
Recorded PD-related mortality was lower among Black than White adults, whereas AD-related mortality showed no statistically significant racial difference.
-
Cognitive staging and everyday function are not interchangeable.
-
Among adults with ADRD, high SDM was associated with greater ACP prevalence in unadjusted analyses, although the fully adjusted association was not statistically significant.
-
STRUCTURED ABSTRACT INTRODUCTION This study examined the extent to which educational attainment, Alzheimer’s disease (AD) knowledge, and research attitudes are associated with willingness to participate in AD research, and whether AD knowledge and research attitudes mediate associations between educational attainment and willingness to participate.
-
In this trial, $5 and $25 noncontingent monetary incentives included in mailed recruitment letters did not produce a detectable improvement in response among ADRD caregiving dyads.
-
The increasing prevalence of neurodegenerative diseases (NDs), especially Alzheimer's and Parkinson's, is a major public health concern in the Gulf countries (GCs) due to the rapid increase in life expectancy and population aging.
-
GCC countries are experiencing a rapid demographic transition.
-
Retirement timing alone showed limited association with later-life dementia risk, whereas sustained part-time employment and disability-related trajectories were more strongly associated with dementia risk.
-
Recruitment (88.0%) and protocol fidelity (100%) met or exceeded prespecified progression criteria, whereas retention and follow-up data availability were 59.1% (13/22), slightly below the predefined 60% criterion.
-
Among 1,288,359 women, 20,070 with AUD were matched to 100,339 controls.
-
Between 1979 and 2023, AD caused 2,430,795 deaths in U.S. adults.
-
Higher UGS coverage was associated with a lower risk of incident AD among older adults in urban South Korea.
-
Risk prediction in Alzheimer disease can guide follow-up, biomarker testing, trial referral, and prognostic counseling.
-
16/100
Our findings reveal marked geographic variation in dementia risk factors, highlighting the need for region-specific prevention strategies.
-
Internet use for health information was significantly associated with Alzheimer’s disease diagnosis.
-
The dynamics of Alzheimer’s disease spread in aging groups of population are described using an Inflow-Outflow Model.
-
The prognostic significance of psychosis in dementia differs by symptom profile.
-
16/100
The cost-effectiveness of ATTs is strongly influenced by the waning of the treatment effect.
-
We used the September 2013 age-based rollout of the live-attenuated shingles vaccine in England as a natural experiment to estimate the effect of vaccine eligibility on shingles and dementia diagnoses in linked hospital records.
-
People with Down syndrome have higher age-specific mortality rates compared to the general population as well as peers with other intellectual and developmental disabilities.
-
We recommend using a broad (ADRD) algorithm without CMS or medication data, particularly for epidemiological studies or a strict AD algorithm including CMS and medication cases for genetic discovery of late-onset AD associations in VA EMR, and a strict AD algorithm without CMS data for applications focused solely on AD and sensitive to misspecification.
-
Functional–behavioral subtypes can be identified in hospitalized AD patients, supporting multidimensional risk stratification and individualized care planning.
-
POINTER reported a modest structured-versus-self-guided difference in the annual rate of global cognitive change.
-
16/100
Base-case incremental cost-effectiveness ratios (ICERs) for lecanemab versus standard of care were €296,506 per QALY gained, and €371,299 per QALY for donanemab, from the HSE payer perspective under HIQA guidelines.
-
In fixed-effects panel models that accounted for spending persistence, lagged DALYs were not statistically associated with subsequent spending.
-
Previous studies have shown that AD-related costs are mainly driven by long-term informal care.
-
Under calibrated simulation parameters, slowing of cognitive decline emerged as the most important attribute (relative importance 25.7%), followed by annual cost (17.6%), ARIA risk (15.4%), and travel to treatment centre (13.0%).
-
Simulation-based validation demonstrates the framework’s analytical capability.
-
The multifactorial interventions implemented in community settings showed no effect on dementia onset or health outcomes.
-
EOD incidence peaked at 4-5% among beneficiaries with and without cancer.
-
Dementia risk may be increased among people with HIV with certain cancers, including AIDS-defining cancers.
-
STRUCTURED ABSTRACT INTRODUCTION The Dementia DataHub (DDH) reports U.S. dementia prevalence and incidence from Medicare data.
-
Dementia is variably recorded across routine datasets, and the setting in which dementia is first recorded identifies groups with markedly different prognosis.
-
Earlier diagnosis increases total expenditures but improves care and cost allocation.
-
These therapies require complex diagnostic workup and safety monitoring, raising significant budget impact concerns for healthcare payers.
-
Biases in cognitive/functional screening tests may disproportionately exclude ethnoracial minorities in AD prevention trials.
-
PET participants lived longer in community (0.26 years, 95% confidence interval [CI]: 0.05 to 0.45) and overall (0.15, CI: 0.02 to 0.27), but did not have statistically different health insurance (€703, CI: -3974 to 5045) or total costs including institutionalization (-€8258, CI: -20,622 to 3377).
-
A total of 12,764,487 weighted older adults with ADRD were included, with 34.60% of them using anti-dementia drugs.
-
Dementia was diagnosed at a mean of 5.1 ± 3.4 years post-KTx.
-
Eighty-one percent of eligible participants were not aware of a dementia diagnosis.
-
Individuals from minoritized racial/ethnic groups face a disproportionate burden of Alzheimer's disease and related dementias.
-
AADAPt participants had risk factors for developing dementia in future, such as hypertension and hyperlipidemia, but also reported protective factors such as high social engagement.
-
Of 2 684 704 Fee-for-Service patients with Alzheimer dementia, 769 141 met all inclusion criteria; among these, 281 042 (36.5%) had agitation.
-
The sample included 1 626 127 Medicare beneficiaries (mean [SD] age, 80.1 [8.0] years; 922 194 women [56.7%]) who received diagnoses of the 4 conditions in 2016.
-
ADODs will cost the world economy 14 513 billion international dollars (INT$, measured in the base year 2020; 95% uncertainty interval [UI] 12 106-17 778) from 2020 to 2050, equivalent to 0·421% (95% UI 0·351-0·515) of annual global GDP.
-
43/100
Compared to White participants, Black, Hispanic, and Asian participants reported taking fewer total medications (incidence rate ratio [IRR] ± standard error[SE] = 0.903 ± 0.017, 0.875 ± 0.021, and 0.912 ± 0.041, respectively, all p < 0.01).
-
Among these, 85.5% were non-Hispanic (NH) white, 8% NH black, 4.34% Hispanic or Latino, 1.6% NH Asian or Pacific Islander, and 0.3% NH American Indian or Alaska Native adults.
-
Compared to non-Hispanic or Latino (NH) White participants, Hispanic or Latino (3.52 points, 95% confidence interval [CI]: [2.61, 4.42]); NH Asian (2.97 points, 95% CI: [1.71, 4.22]); and NH Black participants (2.79 points, 95% CI: [1.96, 3.63]) participants demonstrated higher levels of endorsement of the VPAI items at baseline.
-
NPS were present in 95% in at least one time point.
From across this tag
8 of the 265 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.
- Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data
- Epidemiological and economic burden of Alzheimer's disease: a systematic literature review of data across Europe and the United States of America
- The China Alzheimer Report 2022
- Blindness and Visual Impairment in the Medicare Population: Disparities and Association with Hip Fracture and Neuropsychiatric Outcomes
- Racial and Ethnic Differences in Knowledge About One's Dementia Status
- Racial and Ethnic Disparities in Dementia Risk Among Individuals With Low Education
- Alzheimer's Disease and Alzheimer's Disease-Related Dementias in African Americans: Focus on Caregivers
- Racial/ethnic disparities in initiation and persistent use of anti-dementia medications